跳至主要内容
临床试验/NCT03143751
NCT03143751已完成3 期

Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients Study Protocol for a Multicenter Randomized Open-label Trial With Blinded Adjudication of Primary Outcome

Nantes University Hospital10 个研究点 分布在 1 个国家目标入组 370 人开始时间: 2017年10月31日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
370
试验地点
10
主要终点
Score on the Extended Glasgow Outcome Scale (GOS-E) at 6 months

研究概览

简要总结

Traumatic brain injury (TBI) is a major cause of death and severe prolonged disability. Intracranial hypertension (ICH) is a critical risk factor of bad outcomes after TBI. Continuous infusion of hyperosmolar therapy has been proposed for the prevention or the treatment of ICH. Whether an early administration of continuous hyperosmolar therapy improves long term outcomes is uncertain. The aim of the current study is to assess the efficiency and the safety of continuous hyperosmolar therapy in TBI patients.

The COBI trial is the first randomized controlled trial powered to investigate whether continuous hyperosmolar therapy in TBI patients improve long term recovery.

Hypothesis

Patients treated with early continuous hyperosmolar therapy have reduced morbidity and mortality rates compared to those receiving standard care alone after traumatic brain injury.

Research Questions

  1. Does early continuous hyperosmolar therapy reduce morbidity and mortality rates at 3 and 6 months after TBI assessed by the GOSE questionnaire?
  2. Does early continuous hyperosmolar therapy prevent intracranial hypertension?

详细描述

Background Traumatic brain injury (TBI) is a major cause of death and severe prolonged disability. Intracranial hypertension (ICH) is a critical risk factor of bad outcomes after TBI.

Continuous infusion of hyperosmolar therapy has been proposed for the prevention or the treatment of ICH. Whether an early administration of continuous hyperosmolar therapy improves long term outcomes is uncertain. The aim of the current study is to assess the efficiency and the safety of continuous hyperosmolar therapy in TBI patients.

Methods The COBI (Continuous hyperosmolar therapy in traumatic brain-injured patients) trial is a multicenter, randomized, controlled, open-label, two-arms study with blinded adjudication of primary outcome. Three hundred and seventy patients hospitalized in Intensive Care Unit with a traumatic brain injury (Glasgow Coma Scale ≤ 12 and abnormal brain CT-scan) are randomized in the first 24 hours following trauma to standard care or continuous hyperosmolar therapy (NaCl 20%) plus standard care. Continuous hyperosmolar therapy is maintained for at least 48 hours in the treatment group and continued for as long as is necessary to prevent intracranial hypertension. The primary outcome is the score on the Extended Glasgow Outcome Scale (GOS-E) at 6 months. The treatment effect is estimated with ordinal logistic regression adjusted for pre-specified prognostic factors and expressed as a common odds ratio.

Discussion The COBI trial is the first randomized controlled trial powered to investigate whether continuous hyperosmolar therapy in TBI patients improve long term recovery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

盲法说明

Masking: Open label , Masked Roles: Subject and Outcomes assessor

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18-80 years old
  • Moderate to severe traumatic brain injury defined as the association of a Coma Glasgow Scale ≤ 12 together with a traumatic abnormal brain CT-scan
  • Time to inclusion inferior to 24 hours
  • Informed consent (or emergency procedure)

排除标准

  • dependence for daily activity
  • Coma Glasgow Scale of 3 and fixed dilated pupils
  • associated cervical spine injury
  • imminent death and do-not-resuscitate orders
  • pregnancy.
  • Major not legally responsible
  • Oedemato-ascitic decompensation of hepatic cirrhosis
  • State of hydro-sodium retention secondary to heart failure

研究组 & 干预措施

Continuous hyperosmolar therapy

Experimental

Standard cares plus continuous hyperosmolar therapy (NaCl20%)

干预措施: NaCl20% (Continuous hyperosmolar therapy) (Drug)

结局指标

主要结局

Score on the Extended Glasgow Outcome Scale (GOS-E) at 6 months

时间窗: 6 months

The GOS-E is a scale measuring the neurological recovery after traumatic brain injuries

次要结局

  • Blood level of chlore(7 Days)
  • Mortality rate in ICU(6 months)
  • Blood level of sodium(7 Days)
  • Rate of acute kidney injury(28 days)
  • Rate of centropontine myelinolysis(28 days)
  • brain oxygenation (PtiO2)(5 Days)
  • Rate of patients with anterograde amnesia(6 months)
  • blood osmolality(7 Days)
  • Rate of thrombo-embolic events(28 days)
  • Blood level of potassium(5 Days)
  • weight(5 Days)
  • GOS-E(3 months)
  • functional independence measure : ADL (Activities of Daily Living) of Katz(6 months)
  • Short Form 36(6 months)
  • Intracranial pressure control(7 Days)
  • Blood level of pH (Hydrogen Potention)(5 Days)
  • blood level of creatinine(5 Days)
  • Diuresis(5 Days)
  • Ancillary study: questionnaire HADS (Hospital Anxiety and Depression Scale) in patient's relative(6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验